



R  
A  
N  
D  
O  
M  
I  
Z  
A  
T  
I  
O  
N

2  
:  
1

LY2181308 Lead-in (2 days)

**Interim #1**  
21 patients,  
Safety, PK

**Interim #2**  
60 patients,  
Safety, PK

**Primary Analysis**  
120 patients  
CTS

**Final Analyses**  
120 PFS events

**Arm A**  
**LY2181308 + Docetaxel (N=120, LY2181308 750 mg once weekly; 75 mg/m<sup>2</sup> docetaxel on Day 1 per three-week cycle)**

**Arm B**  
**Docetaxel (N=60, 75 mg/m<sup>2</sup> on Day 1 per three-week cycle)**